---
title: å“Œç”²é…¯
description: 
published: true
date: 2026-01-30T09:40:04.252Z
tags: freeodwikiæ˜¯ä¸€ä¸ªå¼€æºé¡¹ç›®ï¼Œæä¾›æœ‰å…³odã€overdoseã€è¯ç‰©æ»¥ç”¨ã€è¯ç‰©è¿‡é‡ã€å¸æ¯’ã€æ¯’å“ã€ç¦æ¯’ç­‰è¯é¢˜çš„çŸ¥è¯†ã€‚
editor: markdown
dateCreated: 2026-01-30T05:58:01.722Z
---

# å“Œç”²é…¯
[â—€è¿”å›è¯ç‰©](/è¯ç‰©.md)

>
> ä¸Šç”Ÿç‰©è¯¾ä¸­ï¼Œè®²åˆ°ç¥ç»è°ƒèŠ‚......
>
> ç”Ÿç‰©è€å¸ˆ(*æ•²é»‘æ¿*)ï¼šè¿™æ˜¯å¯å¡å› ï¼Œä¼šæŠ‘åˆ¶å¤šå·´èƒºè½¬è¿ä½“ï¼Œå¯¼è‡´å¤šå·´èƒºæµ“åº¦å¼‚å¸¸å‡é«˜ï¼Œå±äºæ¯’å“ï¼åŒå­¦ä»¬ççˆ±ç”Ÿå‘½è¿œç¦»æ¯’å“å“ˆ
>
> è¿‡äº†ä¸€ä¼šå„¿ï¼Œ
>
> ç”Ÿç‰©è€å¸ˆ(*è‹¥æœ‰æ‰€æ€*)ï¼šè¿™æ˜¯å“Œç”²é…¯ï¼Œæ˜¯èªæ˜è¯ï¼æ¯•ç«Ÿå°±ç®—ä½ ç†¬å¤œåˆ·é¢˜ï¼Œçªè§¦ä¸å…´å¥‹ä¹Ÿæ²¡æœ‰ç”¨å“ˆã€‚æˆ‘ä»¬åŒ»å­¦ç³»çš„å­¦ç”Ÿï¼Œæ¯é€¢æœŸæœ«è€ƒè¯•ï¼Œç»å¸¸ç»™è‡ªå·±å¼€ä¸€ç“¶å“Œç”²é…¯ç”¨æ¥åˆ·é¢˜ï¼Œå¾ˆç®¡ç”¨ï¼
>

<mark>è¿™ä¸€ç¯‡ç¿»è¯‘å¾—ä¸é”™ï¼Œå¯æƒœæœ‰ä¸€äº›æœ¯è¯­æ²¡æœ‰ææ¸…æ¥šï¼Œæœ‰äº›é“¾æ¥ä¹Ÿæ²¡å¼„å¥½ï¼Œè°¨æ…é˜…è¯»ï¼</mark>

| å“Œç”²é…¯ (Methylphenidate) | |
| --- | --- |
| **åŒ–å­¦å‘½å** | |
| ä¿—å | *Methylphenidate, Concerta, Methylin, Ritalin, Equasym XL* |
| å–ä»£åç§° | *Methylphenidate* |
| ç³»ç»Ÿå‘½åæ³• | *Methyl 2-phenyl-2-piperidin-2-ylacetate* |
| **åˆ†ç±»** | |
| ç²¾ç¥è¯ç‰©ç±»å‹ | *[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)* |
| åŒ–å­¦ç±»å‹ | *[å“Œå•¶ä¹™é…¸é…¯ (Phenidate)](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¯ç‰©å…¨ç´¢å¼•.md)* |

<br>

## ç»™è¯é€”å¾„
> **è­¦å‘Š**ï¼šç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·å§‹ç»ˆä»ä½å‰‚é‡å¼€å§‹ã€‚è¯·å‚é˜…[è´Ÿè´£ä»»çš„ç”¨è¯](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ)
{.is-warning}

> å…è´£å£°æ˜ï¼š æ­¤å¤„çš„å‰‚é‡ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œç›¸å…³èµ„æºï¼Œä»…ç”¨äºæ•™è‚²ç›®çš„ã€‚å®ƒä¸æ˜¯åŒ»ç–—å»ºè®®ï¼Œä¸ºäº†å‡†ç¡®æ€§åº”ä¸å…¶ä»–æ¥æºè¿›è¡Œæ ¸å®ã€‚
{.is-info}

## ç»™è¯é€”å¾„ {.tabset}

### å£æœ
#### è®¡é‡
| é˜ˆå€¼ | è½»å¾® | ä¸­ç­‰ | å¼ºçƒˆ | ä¸¥é‡ |
| :-: | :-: | :-: | :-: | :-: |
| 5 mg | 10 - 20 mg | 20 - 40 mg | 40 - 60 mg | 60 mg + |
#### æŒç»­æ—¶é—´
| æ€»æ—¶ | èµ·æ•ˆ | ä¸Šå‡ | é¡¶å³° | æ¶ˆé€€ | åé— |
| :-: | :-: | :-: | :-: | :-: | :-: |
| 2.5 - 4 å°æ—¶ | 30 - 60 åˆ†é’Ÿ | 20 - 45 åˆ†é’Ÿ | 60 - 90 åˆ†é’Ÿ | 45 - 60 åˆ†é’Ÿ | 2 - 6 å°æ—¶


| **ç”Ÿç‰©åˆ©ç”¨åº¦** | 11 - 52% |
| :-: | :-: |

### é¼»å¸

#### è®¡é‡
| é˜ˆå€¼ | è½»å¾® | ä¸­ç­‰ | å¼ºçƒˆ | ä¸¥é‡ |
| :-: | :-: | :-: | :-: | :-: |
| 1 mg | 2 - 10 mg | 10 - 30 mg | 30 - 60 mg | 60 mg + |
#### æŒç»­æ—¶é—´
| æ€»æ—¶ | èµ·æ•ˆ | ä¸Šå‡ | é¡¶å³° | æ¶ˆé€€ | åé— |
| :-: | :-: | :-: | :-: | :-: | :-: |
| 2 - 4 å°æ—¶ | 5 - 20 åˆ†é’Ÿ | 15 - 40 åˆ†é’Ÿ | 30 - 45 åˆ†é’Ÿ | 2 - 4 å°æ—¶ | 1 - 4 å°æ—¶

## è¯ç‰©è”ç”¨

| [è¯ç‰©è”ç”¨](#Dangerous_interactions) | é£é™©ç­‰çº§ |
| --- | --- |
| é…’ç²¾ | âš ï¸ æ…ç”¨ |
| MXE | ğŸ’” å±é™© |
| è§£ç¦»å‰‚ | âš ï¸ æ…ç”¨ |
| å³ç¾æ²™èŠ¬ | ğŸ’” å±é™© |
| MDMA | ğŸ’” å±é™© |
| å…´å¥‹å‰‚ | ğŸ’” å±é™© |
| 25x-NBOMe | ğŸ’” å±é™© |
| 25x-NBOH | ğŸ’” å±é™© |
| æ›²é©¬å¤š | ğŸ’” å±é™© |
| å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚ (MAOIs) | ğŸ’” å±é™© |
{.dense}

## ç®€ä»‹

**å“Œç”²é…¯**ï¼ˆMethylphenidateï¼Œä¹Ÿç§°ä¸º **MPH**ã€**MPD**ï¼Œå•†å“ååŒ…æ‹¬ **åˆ©ä»–æ— (Ritalin)**ã€**ä¸“æ³¨è¾¾ (Concerta)** å’Œ **Methylin** ç­‰ï¼‰æ˜¯ä¸€ç§ç»å…¸çš„ã€å¼ºæ•ˆçš„[å“Œå•¶ä¹™é…¸é…¯](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¯ç‰©å…¨ç´¢å¼•.md)ç±»[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ã€‚å®ƒæ˜¯[å–ä»£å“Œå•¶ä¹™é…¸é…¯](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¯ç‰©å…¨ç´¢å¼•.md)ç±»ç‰©è´¨çš„æ¯ä½“åŒ–åˆç‰©ï¼Œè¯¥å®¶æ—åŒ…æ‹¬[ä¹™é…¯ (ethylphenidate)](/è¯ç‰©.md) ã€[å¼‚ä¸™é…¯ (isopropylphenidate)](/è¯ç‰©.md) ç­‰ã€‚å…¶ä½œç”¨æœºåˆ¶æ¶‰åŠå¢åŠ ç¥ç»é€’è´¨[å¤šå·´èƒº](/è¯ç‰©.md)å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/è¯ç‰©.md)çš„æµ“åº¦ã€‚

å®ƒäº1944å¹´é¦–æ¬¡åˆæˆï¼Œå¹¶äº1955å¹´åœ¨ç¾å›½è·å‡†ç”¨äºåŒ»ç–—ç”¨é€”ã€‚æœ€åˆç”±ç‘å£«CIBAå…¬å¸ï¼ˆç°ä¸ºè¯ºå Novartisï¼‰é”€å”®ã€‚å®ƒè¢«æ‰¹å‡†ç”¨äºæ²»ç–—æ³¨æ„åŠ›ç¼ºé™·å¤šåŠ¨éšœç¢ (ADHD) å’Œå‘ä½œæ€§ç¡ç—…ã€‚æ‚£æœ‰æˆ–æœªæ‚£æœ‰ ADHD çš„å­¦ç”Ÿå¸¸å°†å…¶ä½œä¸ºè®¤çŸ¥å¢å¼ºå‰‚å’Œå­¦ä¹ è¾…åŠ©å·¥å…·ä½¿ç”¨ã€‚

[ä¸»è§‚æ•ˆåº”](../æ–‡æ¡£/home.md)åŒ…æ‹¬[åˆºæ¿€](../è¯æ•ˆ/åˆºæ¿€.md)ã€[ä¸“æ³¨åº¦å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)ã€[åŠ¨æœºå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)ã€[æ€§æ¬²å¢å¼º](../è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)ã€[é£Ÿæ¬²æŠ‘åˆ¶](../è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md)å’Œ[æ¬£å¿«æ„Ÿ](../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)ã€‚å®ƒé€šå¸¸å£æœæœç”¨ï¼Œä½†ä¹Ÿå¯ä»¥[é¼»å¸æˆ–ç›´è‚ ç»™è¯](../æ–‡æ¡£/home.md)ã€‚å…¶æ•ˆæœä¸å®‰éä»–å‘½ç›¸å½“ï¼›ç„¶è€Œï¼Œæ®æŠ¥é“å®ƒäº§ç”Ÿçš„æ¬£å¿«æ„Ÿè¾ƒå°‘ï¼Œé€šå¸¸å¨±ä¹ä»·å€¼è¾ƒä½ã€‚ä¸€äº›ç”¨æˆ·è¿˜æŠ¥å‘Šè¯´ï¼Œç›¸å¯¹äºå®‰éä»–å‘½ï¼Œå®ƒä¼šäº§ç”Ÿæ›´å¼ºçƒˆçš„è¯æ•ˆæ¶ˆé€€æœŸï¼ˆcomedownï¼‰ï¼Œå°¤å…¶æ˜¯åœ¨é«˜å‰‚é‡ä¸‹ã€‚

å®ƒå…·æœ‰ä¸­ç­‰çš„æ»¥ç”¨æ½œåŠ›ã€‚é•¿æœŸä½¿ç”¨ï¼ˆå³é«˜å‰‚é‡ã€é‡å¤ç»™è¯ï¼‰ä¸[å¼ºè¿«æ€§é‡å¤ç”¨è¯](../æ–‡æ¡£/home.md)ã€è€å—æ€§å‡çº§å’Œå¿ƒç†ä¾èµ–æœ‰å…³ã€‚å¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/home.md)ã€‚

## å†å²ä¸æ–‡åŒ–

è¯¥åŒ–åˆç‰©ç”±åŒ–å­¦å®¶ Leandro Panizzon äº1944å¹´é¦–æ¬¡åˆæˆï¼Œå¹¶äº1954å¹´ç”±ç‘å£«CIBAå…¬å¸ï¼ˆç°ä¸ºè¯ºåï¼‰ä»¥â€œåˆ©ä»–æ— (Ritalin)â€çš„åç§°ä¸Šå¸‚é”€å”®ã€‚â€œåˆ©ä»–æ—â€è¿™ä¸ªåå­—æºäº Panizzon å¦»å­çš„åå­— Marguerite çš„æ˜µç§° Ritaï¼Œå¥¹ä½¿ç”¨åˆ©ä»–æ—æ¥å¼¥è¡¥ä½è¡€å‹çš„é—®é¢˜ã€‚

ç›´åˆ°1954å¹´ï¼Œå“Œç”²é…¯æ‰è¢«æŠ¥é“ä¸ºä¸€ç§å…´å¥‹å‰‚ã€‚è¯¥è¯ç‰©äº1957å¹´åœ¨ç¾å›½å¼•å…¥åŒ»ç–—ç”¨é€”ã€‚è™½ç„¶æœ€åˆç”¨äºç¼“è§£[å·´æ¯”å¦¥ç±»è¯ç‰©](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)å¼•èµ·çš„æ˜è¿·ã€å‘ä½œæ€§ç¡ç—…å’ŒæŠ‘éƒç—‡ï¼Œåæ¥å®ƒè¢«ç”¨äºæ²»ç–—è€å¹´äººçš„è®°å¿†ç¼ºé™·ã€‚ç›´åˆ°1990å¹´ä»£ï¼Œéšç€åŒ»å­¦å’Œå¿ƒç†å¥åº·ç•Œå¯¹ ADHD è¯Šæ–­çš„æ›´å¥½ç†è§£å’Œæ™®éæ¥å—ï¼Œå…¶äº§é‡å’Œå¤„æ–¹é‡æ‰æ˜¾ç€å¢åŠ ï¼Œå°¤å…¶æ˜¯åœ¨ç¾å›½ã€‚

2000å¹´ï¼ŒAlza Corporation è·å¾—ç¾å›½ FDA æ‰¹å‡†é”€å”® Concertaï¼ˆä¸“æ³¨è¾¾ï¼‰ï¼Œè¿™æ˜¯ä¸€ç§å“Œç”²é…¯çš„ç¼“é‡Šå‰‚å‹ã€‚

æ®ä¼°è®¡ï¼Œ2013å¹´å…¨çƒä½¿ç”¨çš„å“Œç”²é…¯å‰‚é‡æ¯”2012å¹´å¢åŠ äº†66%ã€‚2022å¹´ï¼Œå®ƒæ˜¯ç¾å›½ç¬¬32å¤§å¤„æ–¹è¯ï¼Œå¤„æ–¹é‡è¶…è¿‡1700ä¸‡ä»½ã€‚å®ƒå¯ä»¥ä½œä¸ºé€šç”¨åè¯ç‰©è·å¾—ã€‚

## åŒ–å­¦

å“Œç”²é…¯æ˜¯ä¸€ç§å±äº[å–ä»£è‹¯ä¹™èƒº](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¯ç‰©å…¨ç´¢å¼•.md)å’Œ[å–ä»£å“Œå•¶ä¹™é…¸é…¯](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¯ç‰©å…¨ç´¢å¼•.md)ç±»çš„åˆæˆåˆ†å­ã€‚å®ƒåŒ…å«ä¸€ä¸ªè‹¯ä¹™èƒºæ ¸å¿ƒï¼Œå…¶ç‰¹å¾æ˜¯ä¸€ä¸ªè‹¯ç¯é€šè¿‡ä¹™åŸºé“¾ç»“åˆåˆ°ä¸€ä¸ªæ°¨åŸº (-NH2) ä¸Šã€‚

å®ƒåœ¨ç»“æ„ä¸Šç±»ä¼¼äº[å®‰éä»–å‘½](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ï¼Œå…·æœ‰ RÎ± å¤„çš„å–ä»£ï¼Œè¯¥å–ä»£å¹¶å…¥åˆ°ä¸€ä¸ª[å“Œå•¶](/è¯ç‰©.md)ç¯ä¸­ï¼Œæ­¢äºè‹¯ä¹™èƒºé“¾çš„æœ«ç«¯èƒºã€‚æ­¤å¤–ï¼Œå®ƒåŒ…å«ä¸€ä¸ªç»“åˆåˆ°å…¶ç»“æ„ RÎ² ä¸Šçš„ç”²åŸºç¾§é…¸é…¯ã€‚

### å³æ—‹å“Œç”²é…¯ (Dexmethylphenidate)

å“Œç”²é…¯æ˜¯ä¸€ç§æ‰‹æ€§åŒ–åˆç‰©ï¼Œé€šå¸¸ä½œä¸ºå¤–æ¶ˆæ—‹æ··åˆç‰©ç”Ÿäº§ã€‚å®ƒæœ‰ä¸€ç§ä¹Ÿä½œä¸ºè¯ç‰©é”€å”®çš„å¯¹æ˜ çº¯ä½“ï¼›å³æ—‹å¯¹æ˜ çº¯ä½“è¢«ç§°ä¸ºâ€œ**å³æ—‹å“Œç”²é…¯ (dexmethylphenidate)**â€ï¼Œé€šå¸¸ä»¥ **Focalin** å’Œ **Focalin XR** çš„åä¹‰é”€å”®ã€‚

ç”±äºè¯¥åˆ†å­å…·æœ‰ä¸¤ä¸ªæ‰‹æ€§ä¸­å¿ƒï¼Œå› æ­¤å¯èƒ½å­˜åœ¨å››ç§å“Œç”²é…¯å¼‚æ„ä½“ã€‚åŒºåˆ†äº†ä¸€å¯¹è‹å¼ (threo) å¼‚æ„ä½“å’Œä¸€å¯¹èµ¤å¼ (erythro) å¼‚æ„ä½“ï¼Œå…¶ä¸­ä¸»è¦æ˜¯ d-è‹å¼-å“Œç”²é…¯è¡¨ç°å‡ºè¯ç†å­¦ä¸Šé¢„æœŸçš„æ•ˆæœã€‚

èµ¤å¼éå¯¹æ˜ å¼‚æ„ä½“æ˜¯*å‡å‹*èƒºï¼Œè¿™æ˜¯è‹å¼éå¯¹æ˜ å¼‚æ„ä½“æ‰€ä¸å…·å¤‡çš„ç‰¹æ€§ã€‚å½“è¯ç‰©é¦–æ¬¡æ¨å‡ºæ—¶ï¼Œå®ƒæ˜¯ä»¥ 4:1 çš„èµ¤å¼:è‹å¼éå¯¹æ˜ å¼‚æ„ä½“æ··åˆç‰©é”€å”®çš„ï¼Œä½†åæ¥é‡æ–°é…åˆ¶ä¸ºä»…åŒ…å«è‹å¼éå¯¹æ˜ å¼‚æ„ä½“ã€‚â€œTMPâ€æ˜¯æŒ‡ä¸å«ä»»ä½•èµ¤å¼éå¯¹æ˜ å¼‚æ„ä½“çš„è‹å¼äº§å“ï¼Œå³ (Â±)-è‹å¼-å“Œç”²é…¯ã€‚ç”±äºè‹å¼å¼‚æ„ä½“åœ¨èƒ½é‡ä¸Šæ˜¯æœ‰åˆ©çš„ï¼Œå› æ­¤å¾ˆå®¹æ˜“å·®å‘å¼‚æ„åŒ–æ‰ä»»ä½•ä¸éœ€è¦çš„èµ¤å¼å¼‚æ„ä½“ã€‚

ä»…åŒ…å«å³æ—‹å“Œç”²é…¯çš„è¯ç‰©æœ‰æ—¶è¢«ç§°ä¸º d-TMPï¼Œå°½ç®¡è¿™ä¸ªåç§°å¾ˆå°‘ä½¿ç”¨ï¼Œæ›´å¸¸ç”¨çš„æ˜¯ dexmethylphenidateã€d-MPH æˆ– d-threo-methylphenidateã€‚å·²æœ‰å…³äºå¯¹æ˜ ä½“çº¯ (2*R*,2'*R*)-(+)-*è‹å¼*-å“Œç”²é…¯ç›é…¸ç›åˆæˆçš„ç»¼è¿°å‘è¡¨ã€‚

## è¯ç†å­¦

å“Œç”²é…¯ä¸»è¦ä½œä¸ºä¸€ç§[å»ç”²è‚¾ä¸Šè…ºç´ ](/è¯ç‰©.md)-[å¤šå·´èƒº](/è¯ç‰©.md)[é‡æ‘„å–æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¯ç‰©å…¨ç´¢å¼•.md) (NDRI)ã€‚å®ƒåœ¨è°ƒèŠ‚å¤šå·´èƒºæ°´å¹³æ–¹é¢æœ€æ´»è·ƒï¼Œåœ¨è¾ƒå°ç¨‹åº¦ä¸Šè°ƒèŠ‚å»ç”²è‚¾ä¸Šè…ºç´ ã€‚å“Œç”²é…¯ç»“åˆå¹¶é˜»æ–­å¤šå·´èƒºè½¬è¿ä½“å’Œå»ç”²è‚¾ä¸Šè…ºç´ è½¬è¿ä½“ã€‚

è™½ç„¶[å®‰éä»–å‘½](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)å’Œå“Œç”²é…¯éƒ½æ˜¯å¤šå·´èƒºèƒ½è¯ç‰©ï¼Œä½†åº”æ³¨æ„å®ƒä»¬çš„ä½œç”¨æ–¹å¼æœ‰æ‰€ä¸åŒã€‚å…·ä½“è€Œè¨€ï¼Œå“Œç”²é…¯æ˜¯ä¸€ç§å¤šå·´èƒºé‡æ‘„å–æŠ‘åˆ¶å‰‚ï¼Œè€Œå®‰éä»–å‘½æ—¢æ˜¯[å¤šå·´èƒº](/è¯ç‰©.md)å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/è¯ç‰©.md)çš„é‡Šæ”¾å‰‚åˆæ˜¯é‡æ‘„å–æŠ‘åˆ¶å‰‚ã€‚è¿™ä¸¤ç§è¯ç‰©å¯¹å»ç”²è‚¾ä¸Šè…ºç´ éƒ½æœ‰ç›¸åº”çš„å½±å“ï¼Œè¿™æ¯”å®ƒä»¬å¯¹å¤šå·´èƒºçš„å½±å“è¦å¼±ã€‚

å“Œç”²é…¯åœ¨å¤šå·´èƒº-å»ç”²è‚¾ä¸Šè…ºç´ é‡Šæ”¾å¤„çš„ä½œç”¨æœºåˆ¶ä»æœ‰äº‰è®®ï¼Œä½†åœ¨æ ¹æœ¬ä¸Šä¸å¤§å¤šæ•°å…¶ä»–è‹¯ä¹™èƒºè¡ç”Ÿç‰©ä¸åŒï¼Œå› ä¸ºå“Œç”²é…¯è¢«è®¤ä¸ºä¼šå¢åŠ ä¸€èˆ¬çš„æ”¾ç”µç‡ï¼Œè€Œå®‰éä»–å‘½é€šè¿‡æ¿€æ´» TAAR1 é™ä½æ”¾ç”µç‡å¹¶é€†è½¬å•èƒºçš„æµåŠ¨ã€‚

## ä¸»è§‚æ•ˆåº”

***å…è´£å£°æ˜ï¼š** ä¸‹åˆ—æ•ˆåº”å¼•ç”¨è‡ª [***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](../æ–‡æ¡£/home.md) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](../æ–‡æ¡£/home.md) è´¡çŒ®è€…ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”å¸¦ç€å¥åº·çš„æ€€ç–‘æ€åº¦æ¥çœ‹å¾…å®ƒä»¬ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡é«˜å‰‚é‡æ›´å®¹æ˜“è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚åŒæ ·ï¼Œ**ä¸è‰¯ååº”**åœ¨é«˜å‰‚é‡ä¸‹å˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡** â˜ ã€‚*

### **èº¯ä½“æ•ˆåº”**

*   **[åˆºæ¿€](../è¯æ•ˆ/åˆºæ¿€.md)**ï¼šå“Œç”²é…¯é€šå¸¸è¢«æŠ¥é“å…·æœ‰é«˜åº¦çš„ç²¾åŠ›å’Œç‹¬ç‰¹çš„åˆºæ¿€æ€§ï¼Œç±»ä¼¼äº[å®‰éä»–å‘½](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)æˆ–[å¯å¡å› ](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ï¼Œå¼ºäº[è«è¾¾éå°¼](/è¯ç‰©.md)å’Œ[å’–å•¡å› ](/è¯ç‰©.md)ã€‚åœ¨ä½è‡³ä¸­ç­‰å‰‚é‡ä¸‹ï¼Œå®ƒé¼“åŠ±ä¸€èˆ¬çš„ç”Ÿäº§åŠ›ï¼Œä½†åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå®ƒå¯ä»¥é¼“åŠ±è·³èˆã€ç¤¾äº¤ã€è·‘æ­¥æˆ–æ¸…æ´ç­‰èº«ä½“æ´»åŠ¨ã€‚å“Œç”²é…¯å‘ˆç°å‡ºçš„ç‰¹å®šåˆºæ¿€é£æ ¼å¯ä»¥æè¿°ä¸ºå¼ºè¿«æ€§çš„ã€‚è¿™æ„å‘³ç€åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œéšç€ä¸‹å·´ç´§å’¬ã€ä¸è‡ªä¸»çš„èº«ä½“é¢¤æŠ–å’ŒæŒ¯åŠ¨å‡ºç°ï¼Œå˜å¾—éš¾ä»¥æˆ–ä¸å¯èƒ½ä¿æŒé™æ­¢ï¼Œå¯¼è‡´å…¨èº«æåº¦é¢¤æŠ–ã€åŒæ‰‹ä¸ç¨³å’Œæ™®éç¼ºä¹è¿åŠ¨æ§åˆ¶ã€‚
*   **[è‡ªå‘çš„èº¯ä½“æ„Ÿè§‰](../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)**
*   **[å¿ƒç‡å¢å¿«](../è¯æ•ˆ/å¿ƒç‡å¢å¿«.md)**
*   **[å¿ƒå¾‹å¼‚å¸¸](../è¯æ•ˆ/å¿ƒå¾‹å¼‚å¸¸.md)**
*   **[è„±æ°´](../è¯æ•ˆ/è„±æ°´.md)**
*   **[å°¿é¢‘](../è¯æ•ˆ/å°¿é¢‘.md)**
*   **[å£å¹²](../è¯æ•ˆ/å£å¹².md)**
*   **[é£Ÿæ¬²æŠ‘åˆ¶](../è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md)**
*   **[å‡ºæ±—å¢åŠ ](../è¯æ•ˆ/å‡ºæ±—å¢åŠ .md)**
*   **[æ¶å¿ƒ](../è¯æ•ˆ/æ¶å¿ƒ.md)** - å¯èƒ½å‘ç”Ÿåœ¨é«˜å‰‚é‡ä¸‹ï¼Œå°½ç®¡å¾€å¾€ä¼šåœ¨çŸ­æ—¶é—´å†…æ¶ˆé€€ã€‚
*   **[å¤´æ™•](../è¯æ•ˆ/å¤´æ™•.md)**
*   **[ç£¨ç‰™](../è¯æ•ˆ/ç£¨ç‰™.md)** - é«˜å‰‚é‡ä¸‹å¯èƒ½å‡ºç°ç£¨ç‰™ã€‚ç„¶è€Œï¼Œå®ƒä¸å¦‚ [MDMA](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) é‚£ä¹ˆå¼ºçƒˆã€‚
*   **[è¡€ç®¡æ”¶ç¼©](../è¯æ•ˆ/è¡€ç®¡æ‰©å¼ .md)** (æ³¨ï¼šåŸæ–‡ä¸º Vasoconstrictionï¼Œå¯¹åº”æœ¯è¯­åº”ä¸ºè¡€ç®¡æ”¶ç¼©ï¼Œè™½ç„¶æ­¤å¤„é“¾æ¥æŒ‡å‘äº†â€œè¡€ç®¡æ‰©å¼ â€æ–‡ä»¶ï¼Œè¿™å¯èƒ½æ˜¯å› ä¸ºæ–‡ä»¶æ ‘ä¸­åªæœ‰è¡€ç®¡æ‰©å¼ ï¼Œæˆ–éœ€æ ¹æ®æ–‡ä»¶æ ‘å®é™…å«ä¹‰å¤„ç†ï¼Œæ­¤å¤„æ ¹æ®åŸæ–‡ç›´è¯‘ä¸ºè¡€ç®¡æ”¶ç¼©ï¼Œè‹¥æ— å¯¹åº”æ–‡ä»¶åˆ™ä¸åŠ é“¾æ¥æˆ–æŒ‡å‘è¿‘ä¼¼æ–‡ä»¶ï¼Œæ­¤å¤„ä¾æ®ä¸Šä¸‹æ–‡è‹¥æ²¡æœ‰è¡€ç®¡æ”¶ç¼©æ–‡ä»¶ï¼Œæš‚æ—¶ä¸åŠ é“¾æ¥æˆ–æŒ‡å‘home)
*   **[æ€§æ¬²å¢å¼º](../è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)** - é«˜å‰‚é‡çš„å“Œç”²é…¯å¯ä»¥å¢åŠ æ€§æ¬²ã€‚
*   **[ç³å­”æ‰©å¤§](../è¯æ•ˆ/ç³å­”æ‰©å¤§.md)** - è¿™ç§æ•ˆåº”ä»…åœ¨ä¸­ç­‰åˆ°é«˜å‰‚é‡ä»¥åŠä½å…‰ç…§æ¡ä»¶ä¸‹æ‰ä¼šå‡ºç°ï¼Œå¹¶ä¸”åœ¨è¯æ•ˆæ¶ˆé€€æœŸæ›´ä¸ºçªå‡ºã€‚

### **è®¤çŸ¥æ•ˆåº”**

*   **[ç„¦è™‘](../æ–‡æ¡£/home.md)** - ç›¸æ¯”å…¶ä»–å¸¸è§å…´å¥‹å‰‚å¦‚[å®‰éä»–å‘½](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)æˆ–[å¯å¡å› ](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ï¼Œç„¦è™‘çš„æŠ¥å‘Šé¢‘ç‡ç¨é«˜ã€‚
*   **[è®¤çŸ¥æ¬£å¿«æ„Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - ä¸[å¯å¡å› ](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ç­‰å…¶ä»–å¼ºæ•ˆå…´å¥‹å‰‚ç›¸æ¯”ï¼Œå“Œç”²é…¯çš„è®¤çŸ¥æ•ˆåº”é€šå¸¸åœ¨ä¸»è§‚ä¸Šè¢«è®¤ä¸ºæ›´æ¸…é†’å’Œâ€œåŠŸèƒ½æ€§â€ã€‚
*   **[è‡ªæˆ‘è†¨èƒ€](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[æƒ…ç»ªæŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - è¿™é€šå¸¸åœ¨è½»å¾®å’Œä¸­ç­‰å‰‚é‡ä¸‹æœ€ä¸ºå¼ºçƒˆï¼Œå¹¶ä¸”æ›´å¤šåœ°æ¥è‡ªåŒ»ç–—ç”¨é€”è€Œéå¨±ä¹ç”¨é€”çš„æŠ¥å‘Šã€‚
*   **[ç°å®è§£ä½“](../è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”%20-%20home.md)** - è¿™ç§æ•ˆåº”é€šå¸¸åœ¨ä¸­/é«˜å‰‚é‡ä¸‹æŠ¥å‘Šã€‚
*   **[ä¸“æ³¨åº¦å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - è¯¥æˆåˆ†åœ¨ä½è‡³ä¸­ç­‰å‰‚é‡ä¸‹æœ€æœ‰æ•ˆï¼Œå› ä¸ºä»»ä½•æ›´é«˜çš„å‰‚é‡é€šå¸¸ä¼šæŸå®³æ³¨æ„åŠ›ã€‚
*   **[æ¸…é†’åº¦](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[è®°å¿†å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - æ²»ç–—å‰‚é‡çš„å“Œç”²é…¯å¯æé«˜æ­£å¸¸åŠŸèƒ½ä¸ªä½“å’Œ ADHD æ‚£è€…åœ¨å·¥ä½œè®°å¿†æµ‹è¯•ä¸­çš„è¡¨ç°ã€‚
*   **[æ—¶é—´æ‰­æ›²](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - è¿™å¯ä»¥æè¿°ä¸ºä½“éªŒåˆ°æ—¶é—´åŠ é€Ÿå’Œæµé€å¾—æ¯”æ¸…é†’æ—¶å¿«å¾—å¤šçš„æ„Ÿè§‰ã€‚
*   **[æ€ç»´åŠ é€Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[æ€ç»´ç»„ç»‡](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[åˆ†æèƒ½åŠ›å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[åŠ¨æœºå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[æš—ç¤ºæ€§æŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[éŸ³ä¹æ¬£èµå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - ä¸å…¶ä»–å¸¸è§å…´å¥‹å‰‚å¦‚[å®‰éä»–å‘½](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)æˆ–[å¯å¡å› ](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ç›¸æ¯”ï¼Œæ®æŠ¥é“è¿™ç§æ•ˆåº”ç›¸å¯¹æ¸©å’Œï¼Œæˆ–ä»…åœ¨é«˜å‰‚é‡ä¸‹å­˜åœ¨ã€‚
*   **[å¼ºè¿«æ€§é‡å¤ç”¨è¯](../æ–‡æ¡£/home.md)** - æœ‰å¼ºè¿«æ€§é‡å¤ç”¨è¯çš„æŠ¥å‘Šï¼Œä½†é¢‘ç‡ä½äºå…¶ä»–å¸¸è§å…´å¥‹å‰‚å¦‚[å®‰éä»–å‘½](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)æˆ–[å¯å¡å› ](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ï¼Œé€šå¸¸å‡ºç°åœ¨é«˜å‰‚é‡æˆ–éå£æœç»™è¯æ—¶ã€‚

### **åé—æ•ˆåº”**

[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ä½“éªŒçš„[è¯æ•ˆä¸‹é™æœŸ](../æ–‡æ¡£/home.md)é€šå¸¸æ„Ÿè§‰æ¯”[é¡¶å³°æœŸ](../æ–‡æ¡£/home.md)è´Ÿé¢å’Œä¸èˆ’æœã€‚è¿™é€šå¸¸è¢«ç§°ä¸ºâ€œcomedownâ€ï¼Œæ˜¯ç”±äºç¥ç»é€’è´¨è€—ç«­è€Œå‘ç”Ÿçš„ã€‚å…¶å½±å“é€šå¸¸åŒ…æ‹¬ï¼š

*   **[ç„¦è™‘](../æ–‡æ¡£/home.md)**
*   **[è®¤çŸ¥ç–²åŠ³](../è¯æ•ˆ/èº¯ä½“ç–²åŠ³.md)**
*   **[æŠ‘éƒ](../æ–‡æ¡£/home.md)**
*   **[æ˜“æ€’](../æ–‡æ¡£/home.md)**
*   **[åŠ¨æœºæŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[å¿ƒç‡å¢å¿«](../è¯æ•ˆ/å¿ƒç‡å¢å¿«.md)**
*   **[æ€ç»´å‡é€Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[æ¸…é†’åº¦](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**

å½“å“Œç”²é…¯ä¸[å®‰éä»–å‘½](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)å’Œ[å’–å•¡å› ](/è¯ç‰©.md)ç­‰å…¶ä»–å…´å¥‹å‰‚ç›¸æ¯”æ—¶ï¼Œå®ƒå…·æœ‰æ›´ç³Ÿç³•çš„åé—æ•ˆåº”ï¼Œè¿™ç±»ä¼¼äº [MDMA](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ã€‚

### ä½“éªŒæŠ¥å‘Š

æè¿°è¯¥åŒ–åˆç‰©æ•ˆåº”çš„è½¶äº‹æŠ¥å‘ŠåŒ…æ‹¬ï¼š

*   [ä½“éªŒï¼šåˆ©ä»–æ— 110mg (å£æœ)](../æ–‡æ¡£/home.md) (é“¾æ¥éœ€æŒ‡å‘å®é™…å­˜åœ¨çš„ä½“éªŒæŠ¥å‘Šæ–‡ä»¶ï¼Œæ­¤å¤„æš‚æŒ‡home)
*   [ä½“éªŒï¼šå“Œç”²é…¯ (45mg, é¼»å¸) - éå‡¡çš„ä¸“æ³¨è¾…åŠ©](../æ–‡æ¡£/home.md)
*   [ä½“éªŒï¼šå“Œç”²é…¯ (é¼»å¸) - æ¸…é†’çš„åˆºæ¿€](../æ–‡æ¡£/home.md)
*   [ä½“éªŒï¼šæ™®ç‘å·´æ— (450mg, å£æœ) + å“Œç”²é…¯ (20mg, å£æœ) - Gaba Flipping](../æ–‡æ¡£/home.md)

æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š
*   [Erowid Experience Vaults: Methylphenidate](https://www.erowid.org/experiences/subs/exp_Pharms_Methylphenidate.shtml)

## æ¯’æ€§ä¸ä¼¤å®³æ½œåŠ›

**æ­¤æ¯’æ€§ä¸ä¼¤å®³æ½œåŠ›éƒ¨åˆ†æ˜¯ä¸€ä¸ª[å°èŠ‚](../æ–‡æ¡£/home.md)ã€‚** å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´ç”šè‡³**æå…¶é”™è¯¯**çš„ä¿¡æ¯ï¼æ‚¨å¯ä»¥å¸®åŠ©æ‰©å±•æˆ–æ›´æ­£å®ƒã€‚
*æ³¨æ„ï¼šå¦‚æœä½¿ç”¨æ­¤ç‰©è´¨ï¼Œè¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶å¹¶ä½¿ç”¨**[ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/home.md)**ã€‚*

å“Œç”²é…¯çš„ä¸­æ¯’å‰‚é‡è¢«è®¤ä¸ºæ˜¯è¶…è¿‡ 2 mg/kg æˆ– 60 mg çš„é€Ÿé‡Šåˆ¶å‰‚ï¼Œæˆ–è¶…è¿‡ 4 mg/kg æˆ– 120 mg çš„å®Œæ•´ç¼“é‡Šåˆ¶å‰‚ã€‚åœ¨ä¸€é¡¹ç ”ç©¶çš„å¤§å¤šæ•°æ¡ˆä¾‹ä¸­ï¼Œå“Œç”²é…¯è¿‡é‡å³ä½¿åœ¨6å²ä»¥ä¸‹çš„å„¿ç«¥ä¸­ä¹Ÿæ˜¯æ— ç—‡çŠ¶çš„æˆ–ç‰¹å¾ä¸ºè½»å¾®ç—‡çŠ¶ã€‚

ç„¶è€Œï¼Œç ”ç©¶ä¸­æœ‰ç›¸å½“ä¸€éƒ¨åˆ†æ‚£è€… (31%) å‡ºç°äº†å…¸å‹çš„å…´å¥‹å‰‚è¿‡é‡ç—‡çŠ¶ï¼Œæœ€å¸¸è§çš„æ˜¯å¿ƒåŠ¨è¿‡é€Ÿã€æ¿€åŠ¨ï¼Œä»¥åŠåå¸¸çš„å—œç¡ã€‚åœ¨2012å¹´å›½å®¶æ¯’ç‰©æ•°æ®ç³»ç»ŸæŠ¥å‘Šä¸­ï¼ŒæŠ¥å‘Šäº†9,787æ¬¡å“Œç”²é…¯æš´éœ²ï¼Œå…¶ä¸­1,609æ¬¡æŠ¥å‘Šæ— ä¸è‰¯ååº”ï¼Œ1,009æ¬¡æŠ¥å‘Šè½»å¾®å½±å“ï¼Œ662æ¬¡æŠ¥å‘Šä¸­åº¦å½±å“ï¼Œ33æ¬¡æŠ¥å‘Šä¸»è¦ç—‡çŠ¶ï¼Œæ²¡æœ‰å¯¼è‡´æ­»äº¡çš„ç—…ä¾‹ã€‚

å¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/home.md)ã€‚

### ä¾èµ–æ€§ä¸æ»¥ç”¨æ½œåŠ›

å°±å…¶è€å—æ€§è€Œè¨€ï¼Œå“Œç”²é…¯å¯ä»¥è¿ç»­å¤šå¤©é•¿æœŸä½¿ç”¨ï¼Œå¹¶ä¸”é€šå¸¸è¢«å¤„æ–¹ä»¥è¿™ç§æ–¹å¼ä½¿ç”¨ã€‚é•¿æœŸé‡å¤ä½¿ç”¨ä¼šå¯¹å“Œç”²é…¯çš„è®¸å¤šæ•ˆåº”äº§ç”Ÿè€å—æ€§ã€‚è¿™å¯¼è‡´ä½¿ç”¨è€…å¿…é¡»æœç”¨è¶Šæ¥è¶Šå¤§çš„å‰‚é‡æ‰èƒ½è¾¾åˆ°ç›¸åŒçš„æ•ˆæœã€‚

åœ¨æ€¥æ€§ï¼ˆå³ä¸€æ¬¡æ€§ï¼‰æš´éœ²çš„æƒ…å†µä¸‹ï¼Œä¸€èˆ¬éœ€è¦å¤§çº¦ 3 - 7 å¤©è€å—æ€§æ‰èƒ½å‡åŠï¼Œ1 - 2 å‘¨æ‰èƒ½æ¢å¤åˆ°åŸºçº¿ï¼ˆåœ¨ä¸å†æ‘„å…¥çš„æƒ…å†µä¸‹ï¼‰ã€‚å“Œç”²é…¯ä¸æ‰€æœ‰å¤šå·´èƒºèƒ½å…´å¥‹å‰‚å­˜åœ¨äº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æ‘„å…¥å“Œç”²é…¯åï¼Œæ‰€æœ‰å…´å¥‹å‰‚çš„æ•ˆæœéƒ½ä¼šé™ä½ã€‚

ä¸å…¶ä»–[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ä¸€æ ·ï¼Œé•¿æœŸä½¿ç”¨å“Œç”²é…¯å¯è¢«è§†ä¸ºå…·æœ‰ä¸­ç­‰æˆç˜¾æ€§ï¼Œå…·æœ‰å¾ˆé«˜çš„æ»¥ç”¨æ½œåŠ›ï¼Œå¹¶ä¸”èƒ½å¤Ÿåœ¨æŸäº›ä½¿ç”¨è€…ä¸­å¼•èµ·å¿ƒç†ä¾èµ–ã€‚å½“æˆç˜¾å½¢æˆåï¼Œå¦‚æœä¸€ä¸ªäººçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æ¸´æœ›å’Œ[æˆ’æ–­ååº”](../æ–‡æ¡£/home.md)ã€‚

ç”±äºå…¶å¯¹å¤šå·´èƒºè½¬è¿ä½“çš„ä½œç”¨ï¼Œå“Œç”²é…¯å…·æœ‰ä¸€å®šçš„æ»¥ç”¨æ½œåŠ›ã€‚å“Œç”²é…¯ä¸å…¶ä»–[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ä¸€æ ·ï¼Œä¼šå¢åŠ å¤§è„‘ä¸­çš„[å¤šå·´èƒº](/è¯ç‰©.md)æ°´å¹³ã€‚ç„¶è€Œï¼Œåœ¨æ²»ç–—å‰‚é‡ä¸‹ï¼Œè¿™ç§å¢åŠ æ˜¯ç¼“æ…¢çš„ï¼Œå› æ­¤å³ä½¿é™è„‰æ³¨å°„ä¹Ÿå¾ˆå°‘å‘ç”Ÿæ¬£å¿«æ„Ÿã€‚å› æ­¤ï¼Œå“Œç”²é…¯çš„æ»¥ç”¨å’Œæˆç˜¾æ½œåŠ›æ˜¾ç€ä½äºå…¶ä»–å¤šå·´èƒºèƒ½å…´å¥‹å‰‚ã€‚

å½“å“Œç”²é…¯è¢«ç²‰ç¢å¹¶[é¼»å¸](../æ–‡æ¡£/home.md)ï¼ˆå—…å¸ï¼‰æˆ–[æ³¨å°„](../æ–‡æ¡£/home.md)æ—¶ï¼Œæ»¥ç”¨æ½œåŠ›ä¼šå¢åŠ ã€‚åº”è¯¥æ³¨æ„çš„æ˜¯ï¼Œç”±äºè¯ä¸¸ä¸­çš„å¡«å……ç‰©ï¼Œè¿™å¯èƒ½å¯¹é¼»è…”æœ‰å®³ï¼Œå¹¶ä¸”é™è„‰æ³¨å°„å¯èƒ½å¯¼è‡´[è‚ºæ°”è‚¿](https://en.wikipedia.org/wiki/Emphysema)ï¼ˆä¸€ç§ä¸‹å‘¼å¸é“ç–¾ç—…ï¼Œå½“ç”±åˆ©ä»–æ—ç‰‡å‰‚å¼•èµ·æ—¶ä¹Ÿç§°ä¸º[åˆ©ä»–æ—è‚º](https://en.wikipedia.org/wiki/Emphysema#Ritalin_lung)ï¼‰ã€‚é™è„‰æ³¨å°„å“Œç”²é…¯ï¼ˆé€šå¸¸ä»¥åˆ©ä»–æ—çš„åä¹‰é”€å”®ï¼Œå¹¶å¹¿æ³›ç”¨ä½œæ²»ç–—æ³¨æ„åŠ›ç¼ºé™·å¤šåŠ¨éšœç¢çš„å…´å¥‹å‰‚è¯ç‰©ï¼‰å¯å¯¼è‡´ç§°ä¸º[åˆ©ä»–æ—è‚º](https://en.wikipedia.org/wiki/Emphysema#Ritalin_lung)çš„è‚ºæ°”è‚¿å˜åŒ–ã€‚

æ»¥ç”¨å“Œç”²é…¯çš„ä¸»è¦æ¥æºæ˜¯ä»åˆæ³•å¤„æ–¹è½¬ç§»ï¼Œè€Œä¸æ˜¯éæ³•åˆæˆã€‚é‚£äº›å‡ºäºåŒ»ç–—ç›®çš„ä½¿ç”¨å“Œç”²é…¯çš„äººé€šå¸¸æŒ‰æŒ‡ç¤ºå£æœæœç”¨ï¼Œè€Œé¼»å†…å’Œé™è„‰æ³¨å°„æ˜¯å¨±ä¹ç”¨é€”çš„é¦–é€‰æ–¹å¼ã€‚

### ç²¾ç¥ç—…

ä¸»æ¡ç›®ï¼š[å…´å¥‹å‰‚ç²¾ç¥ç—…](../æ–‡æ¡£/home.md)

é•¿æœŸä½¿ç”¨ï¼ˆå³é«˜å‰‚é‡ã€é‡å¤ç»™è¯ï¼‰å¯èƒ½ä¼šå¢åŠ æ‚£[ç²¾ç¥ç—…](../æ–‡æ¡£/home.md)çš„é£é™©ã€‚çŸ­æœŸå“Œç”²é…¯æ²»ç–—çš„å®‰å…¨æ€§å·²å¾—åˆ°å……åˆ†ç¡®ç«‹ï¼ŒçŸ­æœŸä¸´åºŠè¯•éªŒæ˜¾ç¤ºï¼Œåœ¨æ²»ç–—å‰‚é‡æ°´å¹³ä¸‹ï¼Œå“Œç”²é…¯è¯±å‘çš„ç²¾ç¥ç—…å‘ç”Ÿç‡éå¸¸ä½ (0.1%)ã€‚

å“Œç”²é…¯å¼•èµ·çš„ç²¾ç¥ç—…ç—‡çŠ¶å¯èƒ½åŒ…æ‹¬[å¹»å¬](../è¯æ•ˆ/è§†è§‰æ•ˆåº”%20-%20home.md)ã€[è§†å¹»è§‰](../è¯æ•ˆ/è§†è§‰æ•ˆåº”%20-%20home.md)ã€ä¼¤å®³è‡ªå·±çš„å†²åŠ¨ã€ä¸¥é‡[ç„¦è™‘](../æ–‡æ¡£/home.md)ã€[èºç‹‚](../æ–‡æ¡£/home.md)ã€[å»æŠ‘åˆ¶](../æ–‡æ¡£/home.md)ã€[åæ‰§å’Œå¤¸å¤§å¦„æƒ³](../æ–‡æ¡£/home.md)ã€[å›°æƒ‘](../æ–‡æ¡£/home.md)ã€[æƒ…ç»ªæŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)ã€æ”»å‡»æ€§å¢åŠ å’Œ[æ˜“æ€’](../æ–‡æ¡£/home.md)ã€‚

### ä¸é…’ç²¾çš„è”ç”¨

å“Œç”²é…¯ï¼ˆå£æœæ—¶ï¼‰çš„ç”Ÿç‰©åˆ©ç”¨åº¦è¾ƒä½ï¼Œçº¦ä¸º30%ã€‚å¦‚æœä¸é…’ç²¾ï¼ˆä¹™é†‡ï¼‰ä¸€èµ·æœç”¨ï¼Œè¡€æµ†ä¸­å³æ—‹å“Œç”²é…¯çš„æ°´å¹³ä¼šå¢åŠ é«˜è¾¾40%ã€‚è¿˜ä¼šå½¢æˆä¸€ç§åä¸º[ä¹™é…¯ (ethylphenidate)](/è¯ç‰©.md) çš„ä»£è°¢ç‰©ã€‚

#### é…’ç²¾è¯±å¯¼çš„å‰‚é‡å€¾æ³» (AIDD)

**é…’ç²¾ä¸ç¼“é‡Šå‰‚å‹è¯ç‰©è”ç”¨å¯èƒ½æ˜¯å±é™©çš„ã€‚**

è¿™ç§å‰‚é‡å€¾æ³»æ•ˆåº”æ˜¯æŒ‡åœ¨æ‘„å…¥ä¹™é†‡çš„åŒæ—¶é€šè¿‡ç¼“é‡Šå‰‚å‹ç»™è¯æ—¶ï¼Œå¤§é‡è¯ç‰©æ„å¤–å¿«é€Ÿé‡Šæ”¾ã€‚è¿™è¢«è®¤ä¸ºæ˜¯è¯ç‰©åŠ£åŠ¿ï¼Œå› ä¸ºé€šè¿‡å¢åŠ å¸æ”¶å’Œè¡€æ¸…æµ“åº¦è¶…è¿‡è¯ç‰©çš„æ²»ç–—çª—å£ï¼Œå¯¼è‡´è¯ç‰©è¯±å‘æ¯’æ€§çš„é£é™©å¾ˆé«˜ã€‚é¢„é˜²è¿™ç§ç›¸äº’ä½œç”¨çš„æœ€ä½³æ–¹æ³•æ˜¯é¿å…åŒæ—¶æ‘„å…¥è¿™ä¸¤ç§ç‰©è´¨ï¼Œæˆ–ä½¿ç”¨ç‰¹å®šçš„æŠ— AIDD çš„æ§é‡Šåˆ¶å‰‚ã€‚

ä½“å¤–æ•°æ®è¡¨æ˜ï¼ŒæŸäº›ç¼“é‡Šå…´å¥‹å‰‚åœ¨é…’ç²¾å­˜åœ¨ä¸‹å¯èƒ½ä¼šç»å†å‰‚é‡å€¾æ³»ã€‚è¿™æ˜¯ä¸€ä¸ªä»¤äººæ‹…å¿§çš„é—®é¢˜ï¼Œå› ä¸º ADHD æ‚£è€…ç¾¤ä½“æœ‰é…—é…’çš„é£é™©ã€‚æœç”¨ç¼“é‡Šå…´å¥‹å‰‚å’Œé…’ç²¾æ—¶å‘ç”Ÿå‰‚é‡å€¾æ³»çš„å¯èƒ½æ€§å¯èƒ½ä¼šç»™ ADHD æ‚£è€…å¸¦æ¥æ„æƒ³ä¸åˆ°çš„å±é™©å‰¯ä½œç”¨ã€‚

ç¼“é‡Šé…æ–¹çš„ä¸€ä¸ªä¾‹å­åŒ…æ‹¬å“Œç”²é…¯è¯ç‰©å“ç‰Œ Concertaï¼ˆä¸“æ³¨è¾¾ï¼‰ã€‚

### å±é™©çš„ç›¸äº’ä½œç”¨

***è­¦å‘Šï¼š*** *è®¸å¤šç²¾ç¥æ´»æ€§ç‰©è´¨å•ç‹¬ä½¿ç”¨æ—¶ç›¸å½“å®‰å…¨ï¼Œä½†ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶å¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨æä¾›äº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…å«æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com), [DuckDuckGo](https://www.duckduckgo.com), [PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆå¯ä»¥å®‰å…¨é£Ÿç”¨ã€‚éƒ¨åˆ†åˆ—å‡ºçš„ç›¸äº’ä½œç”¨æ¥æºäº [TripSit](https://combo.tripsit.me)ã€‚*

*   **[25x-NBOMe](/è¯ç‰©.md) & [25x-NBOH](/è¯ç‰©.md)** - 25x åŒ–åˆç‰©å…·æœ‰é«˜åº¦åˆºæ¿€æ€§ï¼Œå¯¹èº«ä½“æœ‰å‹åŠ›ã€‚åº”ä¸¥æ ¼é¿å…ä¸å“Œç”²é…¯è”ç”¨ï¼Œå› ä¸ºå­˜åœ¨è¿‡åº¦[åˆºæ¿€](../è¯æ•ˆ/åˆºæ¿€.md)å’Œå¿ƒè„è´Ÿè·çš„é£é™©ã€‚è¿™å¯èƒ½å¯¼è‡´[è¡€å‹å‡é«˜](../è¯æ•ˆ/è¡€å‹å‡é«˜.md)ã€[è¡€ç®¡æ”¶ç¼©](../è¯æ•ˆ/è¡€ç®¡æ‰©å¼ .md)ã€æƒŠæå‘ä½œã€[æ€ç»´å¾ªç¯](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)ã€[ç™«ç—«å‘ä½œ](../è¯æ•ˆ/ç™«ç—«å‘ä½œ.md)ï¼Œæå°‘æ•°æƒ…å†µä¸‹ä¼šå¯¼è‡´å¿ƒåŠ›è¡°ç«­ã€‚
*   **[é…’ç²¾](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)** - å°†é…’ç²¾ä¸[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)æ··åˆæ˜¯å±é™©çš„ï¼Œå› ä¸ºå­˜åœ¨æ„å¤–è¿‡åº¦ä¸­æ¯’çš„é£é™©ã€‚å…´å¥‹å‰‚ä¼šæ©ç›–é…’ç²¾çš„[æŠ‘åˆ¶](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ä½œç”¨ï¼Œè€Œå¤§å¤šæ•°äººåˆ©ç”¨è¿™ç§ä½œç”¨æ¥è¯„ä¼°ä»–ä»¬çš„é†‰é…’ç¨‹åº¦ã€‚ä¸€æ—¦å…´å¥‹å‰‚æ¶ˆé€€ï¼Œ[æŠ‘åˆ¶](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ä½œç”¨å°†ä¸å†å—å¯¹æŠ—ï¼Œè¿™å¯èƒ½å¯¼è‡´æ–­ç‰‡å’Œä¸¥é‡çš„[å‘¼å¸æŠ‘åˆ¶](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚å¦‚æœæ··åˆä½¿ç”¨ï¼Œä½¿ç”¨è€…åº”ä¸¥æ ¼é™åˆ¶æ¯å°æ—¶é¥®ç”¨çš„é…’ç²¾é‡ã€‚
*   **[å³ç¾æ²™èŠ¬ (DXM)](../è¯ç‰©/å³ç¾æ²™èŠ¬.md)** - åº”é¿å…ä¸ DXM è”ç”¨ï¼Œå› ä¸ºå®ƒä¼šæŠ‘åˆ¶[5-ç¾Ÿè‰²èƒº](/è¯ç‰©.md)å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/è¯ç‰©.md)çš„é‡æ‘„å–ã€‚å­˜åœ¨æƒŠæå‘ä½œå’Œé«˜è¡€å‹å±è±¡çš„é£é™©å¢åŠ ï¼Œæˆ–è€…ä¸5-ç¾Ÿè‰²èƒºé‡Šæ”¾å‰‚ï¼ˆ[MDMA](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ã€[ç”²å¡è¥¿é…®](/è¯ç‰©.md)ã€[ç”²æ°§éº»é»„é…®](/è¯ç‰©.md)ç­‰ï¼‰è”ç”¨æ—¶å­˜åœ¨[5-ç¾Ÿè‰²èƒºç»¼åˆå¾](../æ–‡æ¡£/home.md)çš„é£é™©ã€‚ä»”ç»†ç›‘æµ‹è¡€å‹å¹¶é¿å…å‰§çƒˆçš„ä½“åŠ›æ´»åŠ¨ã€‚
*   **[MDMA](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)** - å½“å­˜åœ¨å…¶ä»–[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)æ—¶ï¼ŒMDMA çš„ä»»ä½•ç¥ç»æ¯’æ€§ä½œç”¨éƒ½å¯èƒ½å¢åŠ ã€‚è¿˜å­˜åœ¨è¡€å‹è¿‡é«˜å’Œå¿ƒè„è´Ÿè·ï¼ˆå¿ƒè„æ¯’æ€§ï¼‰çš„é£é™©ã€‚
*   **[MXE](/è¯ç‰©.md)** - ä¸€äº›æŠ¥å‘Šè¡¨æ˜ä¸ MXE è”ç”¨å¯èƒ½ä¼šå±é™©åœ°å¢åŠ è¡€å‹ï¼Œå¹¶å¢åŠ [èºç‹‚](../æ–‡æ¡£/home.md)å’Œ[ç²¾ç¥ç—…](../æ–‡æ¡£/home.md)çš„é£é™©ã€‚
*   **[è§£ç¦»å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)** - è¿™ä¸¤ç±»è¯ç‰©éƒ½æœ‰[å¦„æƒ³](../æ–‡æ¡£/home.md)ã€[èºç‹‚](../æ–‡æ¡£/home.md)å’Œ[ç²¾ç¥ç—…](../æ–‡æ¡£/home.md)çš„é£é™©ï¼Œè”ç”¨æ—¶è¿™äº›é£é™©å¯èƒ½ä¼šæˆå€å¢åŠ ã€‚
*   **[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)** - å“Œç”²é…¯ä¸[å¯å¡å› ](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ç­‰å…¶ä»–[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)è”ç”¨å¯èƒ½æ˜¯å±é™©çš„ï¼Œå› ä¸ºå®ƒä»¬ä¼šä½¿äººçš„[å¿ƒç‡](../è¯æ•ˆ/å¿ƒç‡å¢å¿«.md)å’Œ[è¡€å‹](../è¯æ•ˆ/è¡€å‹å‡é«˜.md)å‡é«˜åˆ°å±é™©æ°´å¹³ã€‚
*   **[æ›²é©¬å¤š](/è¯ç‰©.md)** - å·²çŸ¥æ›²é©¬å¤šä¼šé™ä½ç™«ç—«å‘ä½œé˜ˆå€¼ï¼Œä¸å…´å¥‹å‰‚è”ç”¨å¯èƒ½ä¼šè¿›ä¸€æ­¥å¢åŠ è¿™ç§é£é™©ã€‚
*   **[å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚ (MAOIs)](/è¯ç‰©.md)** - è¿™ç§ç»„åˆå¯èƒ½ä¼šå°†ç¥ç»é€’è´¨ï¼ˆå¦‚å¤šå·´èƒºï¼‰çš„é‡å¢åŠ åˆ°å±é™©ç”šè‡³è‡´å‘½çš„æ°´å¹³ã€‚ä¾‹å¦‚[éª†é©¼è“¬](../è¯ç‰©/home.md)ã€[*å¡çš®æœ¨*](../è¯ç‰©/home.md)å’Œä¸€äº›[æŠ—æŠ‘éƒè¯](/è¯ç‰©.md)ã€‚

## æ³•å¾‹åœ°ä½

åœ¨å›½é™…ä¸Šï¼Œæ ¹æ®ç²¾ç¥è¯ç‰©å…¬çº¦ï¼Œå“Œç”²é…¯æ˜¯é™„è¡¨ II è¯ç‰©ã€‚

*   **æ¾³å¤§åˆ©äºš**ï¼šå“Œç”²é…¯æ˜¯â€œé™„è¡¨ 8â€å—æ§ç‰©è´¨ã€‚æ­¤ç±»è¯ç‰©å¿…é¡»åœ¨åˆ†å‘å‰ä¿å­˜åœ¨å¯ä¸Šé”çš„ä¿é™©ç®±ä¸­ï¼Œæ— å¤„æ–¹æŒæœ‰å°†è¢«å¤„ä»¥å·¨é¢ç½šæ¬¾ç”šè‡³ç›‘ç¦ã€‚
*   **å¥¥åœ°åˆ©**ï¼šæ ¹æ® AMGï¼ˆå¥¥åœ°åˆ©è¯å“æ³•ï¼‰ï¼Œå“Œç”²é…¯å¯ç”¨äºåŒ»ç–—ç”¨é€”ï¼Œæ ¹æ® SMGï¼ˆå¥¥åœ°åˆ©éº»é†‰å“æ³•ï¼‰ï¼Œæ— å¤„æ–¹é”€å”®æˆ–æŒæœ‰æ˜¯éæ³•çš„ã€‚
*   **åŠ æ‹¿å¤§**ï¼šå“Œç”²é…¯è¢«åˆ—å…¥ç®¡åˆ¶è¯ç‰©å’Œç‰©è´¨æ³•æ¡ˆçš„é™„è¡¨ IIIï¼ˆè¿åŒ LSDã€è¿·å¹»è˜‘è‡å’Œéº¦å¸å¡æ—ï¼‰ã€‚æ ¹æ®é£Ÿå“å’Œè¯ç‰©æ³•æ¡ˆä¸‹çš„é£Ÿå“å’Œè¯ç‰©æ¡ä¾‹ G éƒ¨åˆ†ï¼ˆç¬¬ G.01.002 èŠ‚ï¼‰ï¼Œæ— å¤„æ–¹æŒæœ‰æ˜¯éæ³•çš„ã€‚
*   **æ³•å›½**ï¼šå“Œç”²é…¯è¢«åˆ—ä¸ºâ€œstupÃ©fiantâ€ï¼Œå³å…¬è®¤çš„æ»¥ç”¨è¯ç‰©ã€‚å®ƒåªèƒ½åœ¨éº»é†‰å“å¤„æ–¹å•ä¸Šå¼€å…·ã€‚
*   **å¾·å›½**ï¼šå“Œç”²é…¯æ˜¯ BtMG Anlage III ä¸‹çš„å—æ§ç‰©è´¨ã€‚å®ƒåªèƒ½åœ¨éº»é†‰å“å¤„æ–¹å•ä¸Šå¼€å…·ã€‚
*   **æ–°è¥¿å…°**ï¼šå“Œç”²é…¯æ˜¯â€œB2 ç±»å—æ§ç‰©è´¨â€ã€‚éæ³•æŒæœ‰å¯åˆ¤å¤„å…­ä¸ªæœˆç›‘ç¦ï¼Œåˆ†å‘å¯åˆ¤å¤„ 14 å¹´ç›‘ç¦ã€‚
*   **ç‘å…¸**ï¼šå“Œç”²é…¯æ˜¯å…·æœ‰å…¬è®¤åŒ»ç–—ä»·å€¼çš„æ¸…å• II å—æ§ç‰©è´¨ã€‚æ— å¤„æ–¹æŒæœ‰æœ€é«˜å¯åˆ¤å¤„ä¸‰å¹´ç›‘ç¦ã€‚
*   **ç‘å£«**ï¼šå“Œç”²é…¯æ˜¯ Verzeichnis A ä¸‹ç‰¹åˆ«å‘½åçš„å—æ§ç‰©è´¨ã€‚å…è®¸åŒ»ç–—ç”¨é€”ã€‚
*   **åœŸè€³å…¶**ï¼šå“Œç”²é…¯æ˜¯ä»…é™â€œçº¢è‰²å¤„æ–¹â€çš„ç‰©è´¨ï¼Œæ— å¤„æ–¹é”€å”®æˆ–æŒæœ‰æ˜¯éæ³•çš„ã€‚
*   **è‹±å›½**ï¼šå“Œç”²é…¯æ˜¯å—æ§çš„â€œB ç±»â€ç‰©è´¨ã€‚æ— å¤„æ–¹æŒæœ‰å¯åˆ¤å¤„æœ€é«˜ 5 å¹´ç›‘ç¦å’Œ/æˆ–æ— ä¸Šé™ç½šæ¬¾ï¼Œä¾›åº”å¯åˆ¤å¤„ 14 å¹´ç›‘ç¦å’Œ/æˆ–æ— ä¸Šé™ç½šæ¬¾ã€‚
*   **ç¾å›½**ï¼šå“Œç”²é…¯è¢«å½’ç±»ä¸ºé™„è¡¨ II å—æ§ç‰©è´¨ï¼Œè¯¥åç§°ç”¨äºå…·æœ‰å…¬è®¤åŒ»ç–—ä»·å€¼ä½†å…·æœ‰é«˜åº¦æ»¥ç”¨æ½œåŠ›çš„ç‰©è´¨ã€‚

å…³äºå“Œç”²é…¯å¯èƒ½å¯¼è‡´è¯ç‰©ç­›æŸ¥ä¸­å®‰éä»–å‘½å‘ˆå‡é˜³æ€§çš„è¯´æ³•æ˜¯ä¸€ä¸ªæ™®éçš„è¯¯åŒºã€‚ç„¶è€Œï¼Œå®éªŒå®¤ç ”ç©¶æœªå‘ç°å…ç–«æµ‹å®šäº¤å‰ååº”ã€‚

## å¦è§

*   [è´Ÿè´£ä»»çš„ä½¿ç”¨](../æ–‡æ¡£/home.md)
*   [å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)
*   [å®‰éä»–å‘½](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)

## å¤–éƒ¨é“¾æ¥

*   [Methylphenidate (Wikipedia)](http://en.wikipedia.org/wiki/Methylphenidate)
*   [Methylphenidate (Erowid Vault)](https://www.erowid.org/pharms/methylphenidate/)
*   [Methylphenidate (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=565)
*   [Methylphenidate (DrugBank)](https://go.drugbank.com/drugs/DB00422)
*   [Dexmethylphenidate (DrugBank)](https://go.drugbank.com/drugs/DB06701)
*   [Methylphenidate (Drugs-Forum)](https://drugs-forum.com/wiki/Methylphenidate)

## æ–‡çŒ®

* Leonard, B. E., McCartan, D., White, J., & King, D. J. (2004). Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharmacology: Clinical and Experimental, 19(3), 151-180. https://doi.org/10.1002/hup.579

## å‚è€ƒæ–‡çŒ®

1. [â†‘](#cite_ref-Health_Canada_-_Ritalin_1-0) "<https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/483/original/Health_Canada_-_Ritalin.PDF?1556050208>"
2. [â†‘](#cite_ref-2) Lange, K. W., Reichl, S., Lange, K. M., Tucha, L., Tucha, O. (December 2010). ["The history of attention deficit hyperactivity disorder"](http://link.springer.com/10.1007/s12402-010-0045-8). *ADHD Attention Deficit and Hyperactivity Disorders*. **2** (4): 241â€“255. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/s12402-010-0045-8](//doi.org/10.1007%2Fs12402-010-0045-8). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1866-6116](//www.worldcat.org/issn/1866-6116).
3. [â†‘](#cite_ref-3) <https://pmc.ncbi.nlm.nih.gov/articles/PMC3000907/#Sec8>
4. [â†‘](#cite_ref-4) Richard L. Myers <https://books.google.com/books?id=a4DuGVwyN6cC&q=named+ritalin+after+his+wife&pg=PA178> ABC-CLIO. p. 178. ISBN 978-0-313-33758-1.
5. [â†‘](#cite_ref-5) Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". *CNS Drugs*. **20** (9): 713â€“738. doi:[10.2165/00023210-200620090-00002](https://link.springer.com/article/10.2165/00023210-200620090-00002). [PMID 16953648.](https://pubmed.ncbi.nlm.nih.gov/16953648/) [S2CID 39535277.](https://www.semanticscholar.org/paper/Methylphenidate-and-its-Isomers-Heal-Pierce/b19872ac87ae24e3cd161a1719d192b9fccffa1b)
6. [â†‘](#cite_ref-6) Wood S, Sage JR, Shuman T, Anagnostaras SG (2014). "Psychostimulants and cognition: A continuum of behavioral and cognitive activation". *Pharmacol Rev*. **66** (1): 193â€“221. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3880463/>
7. [â†‘](#cite_ref-7) Myers RL (August 2007). [*The 100 Most Important Chemical Compounds: A reference guide*.](https://archive.org/details/100mostimportant0000myer) ABC-CLIO. p. 178. [ISBN](/w/index.php?title=ISBN_(identifier)&action=edit&redlink=1 "ISBN (identifier) (page does not exist)") [978-0-313-33758-1](/wiki/Special:BookSources/978-0-313-33758-1 "Special:BookSources/978-0-313-33758-1").
8. [â†‘](#cite_ref-8) Stolerman I (2010). *Encyclopedia of Psychopharmacology*. Berlin, DE / London, UK: Springer. p. 763. ISBN [978-3-540-68698-9](/wiki/Special:BookSources/978-3-540-68698-9 "Special:BookSources/978-3-540-68698-9").
9. [â†‘](#cite_ref-9) Woodworth T (16 May 2000). [DEA Congressional Testimony (Report)](https://web.archive.org/web/20071012061712/http://www.dea.gov/pubs/cngrtest/ct051600.htm). U.S. Drug Enforcement Administration. Archived from [the original](https://www.dea.gov/pubs/cngrtest/ct051600.htm) on 12 October 2007. Retrieved 2 November 2007.
10. [â†‘](#cite_ref-10) ["Concerta- methylphenidate hydrochloride tablet, extended release"](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd). *DailyMed*. 1 July 2021.
11. [â†‘](#cite_ref-11) ["Newly Approved Drug Therapies (637) Concerta, Alza".](https://web.archive.org/web/20101216171133/http://centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637) *CenterWatch*. Archived from [the original](https://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637) on 16 December 2010. Retrieved 30 April 2011.
12. [â†‘](#cite_ref-12) ["Narcotics monitoring board reports 66% increase in global consumption of methylphenidate"](http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/narcotics-monitoring-board-reports-66-increase-in-global-consumption-of-methylphenidate/20068042.article). *The Pharmaceutical Journal*. 2015. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1211/PJ.2015.20068042](//doi.org/10.1211%2FPJ.2015.20068042). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [2053-6186](//www.worldcat.org/issn/2053-6186).
13. [â†‘](#cite_ref-13) ["Methylphenidate Drug Usage Statistics, United States, 2013 - 2022"](https://clincalc.com/DrugStats/Drugs/Methylphenidate). *ClinCalc*. Retrieved 30 August 2024.
14. [â†‘](#cite_ref-14) ["Methylphenidate Hydrochloride Monograph for Professionals".](https://www.drugs.com/monograph/methylphenidate.html) *Drugs.com*. AHFS. Archived from [the original](https://web.archive.org/web/20181003194029/https://www.drugs.com/monograph/methylphenidate-hydrochloride.html) on 19 December 2018. Retrieved 19 December 2018.
15. [â†‘](#cite_ref-15) Heal, D. J., Pierce, D. M. (2006). ["Methylphenidate and its Isomers: Their Role in the Treatment of Attention-Deficit Hyperactivity Disorder Using a Transdermal Delivery System"](http://link.springer.com/10.2165/00023210-200620090-00002). *CNS Drugs*. **20** (9): 713â€“738. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.2165/00023210-200620090-00002](//doi.org/10.2165%2F00023210-200620090-00002). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1172-7047](//www.worldcat.org/issn/1172-7047).
16. [â†‘](#cite_ref-16) Prashad, M. (July 2001). [<379::AID-ADSC379>3.0.CO;2-4 "Approaches to the Preparation of Enantiomerically Pure (2R,2â€²R)-(+)-threo-Methylphenidate Hydrochloride"](https://onlinelibrary.wiley.com/doi/10.1002/1615-4169(200107)343:5). *Advanced Synthesis & Catalysis*. **343** (5): 379â€“392. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/1615-4169(200107)343:5<379::AID-ADSC379>3.0.CO;2-4](//doi.org/10.1002%2F1615-4169%28200107%29343%3A5%3C379%3A%3AAID-ADSC379%3E3.0.CO%3B2-4). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1615-4150](//www.worldcat.org/issn/1615-4150).
17. [â†‘](#cite_ref-17) Heal, D. J., Pierce, D. M. (1 September 2006). ["Methylphenidate and its Isomers"](https://doi.org/10.2165/00023210-200620090-00002). *CNS Drugs*. **20** (9): 713â€“738. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.2165/00023210-200620090-00002](//doi.org/10.2165%2F00023210-200620090-00002). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1179-1934](//www.worldcat.org/issn/1179-1934).
18. â†‘ [18.0](#cite_ref-Iversen2006_18-0) [18.1](#cite_ref-Iversen2006_18-1) Iversen, L. (January 2006). ["Neurotransmitter transporters and their impact on the development of psychopharmacology"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1760736/). *British Journal of Pharmacology*. **147** (Suppl 1): S82â€“S88. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1038/sj.bjp.0706428](//doi.org/10.1038%2Fsj.bjp.0706428). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0007-1188](//www.worldcat.org/issn/0007-1188).
19. [â†‘](#cite_ref-19) Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., Hitzemann, R., Pappas, N. (October 1998). "Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate". *The American Journal of Psychiatry*. **155** (10): 1325â€“1331. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1176/ajp.155.10.1325](//doi.org/10.1176%2Fajp.155.10.1325). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0002-953X](//www.worldcat.org/issn/0002-953X).
20. [â†‘](#cite_ref-20) Focalin XR review | <http://www.pharma.us.novartis.com/product/pi/pdf/focalinXR.pdf>
21. [â†‘](#cite_ref-21) Concerta Xl slow release | <http://www.medicines.org.uk/emc/medicine/8382/SPC/Concerta#PHARMACOLOGICAL_PROPSSPC>
22. â†‘ [22.0](#cite_ref-Montastruc_22-0) [22.1](#cite_ref-Montastruc_22-1) Montastruc, F., Montastruc, G., Montastruc, J.-L., Revet, A. (22 June 2016). ["Cardiovascular safety of methylphenidate should also be considered in adults"](https://www.bmj.com/lookup/doi/10.1136/bmj.i3418). *BMJ*: i3418. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1136/bmj.i3418](//doi.org/10.1136%2Fbmj.i3418). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1756-1833](//www.worldcat.org/issn/1756-1833).
23. â†‘ [23.0](#cite_ref-Leonard_23-0) [23.1](#cite_ref-Leonard_23-1) [23.2](#cite_ref-Leonard_23-2) [23.3](#cite_ref-Leonard_23-3) [23.4](#cite_ref-Leonard_23-4) Leonard, B. E., McCartan, D., White, J., King, D. J. (April 2004). ["Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects"](https://onlinelibrary.wiley.com/doi/10.1002/hup.579). *Human Psychopharmacology: Clinical and Experimental*. **19** (3): 151â€“180. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/hup.579](//doi.org/10.1002%2Fhup.579). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0885-6222](//www.worldcat.org/issn/0885-6222).
24. [â†‘](#cite_ref-24) Nestler, E. J., Hyman, S. E., Malenka, R. C. (2009). *Molecular neuropharmacology: a foundation for clinical neuroscience* (2nd ed ed.). McGraw-Hill Medical. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780071481274](http://en.wikipedia.org/wiki/Special:BookSources/9780071481274 "wikipedia:Special:BookSources/9780071481274"). CS1 maint: Extra text ([link](/w/index.php?title=Category:CS1_maint:_Extra_text&action=edit&redlink=1 "Category:CS1 maint: Extra text (page does not exist)"))
25. [â†‘](#cite_ref-25) Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (24 March 2007). ["Development of a rational scale to assess the harm of drugs of potential misuse"](https://www.sciencedirect.com/science/article/pii/S0140673607604644). *The Lancet*. **369** (9566): 1047â€“1053. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S0140-6736(07)60464-4](//doi.org/10.1016%2FS0140-6736%2807%2960464-4). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0140-6736](//www.worldcat.org/issn/0140-6736).
26. [â†‘](#cite_ref-26) Scharman, E. J., Erdman, A. R., Cobaugh, D. J., Olson, K. R., Woolf, A. D., Caravati, E. M., Chyka, P. A., Booze, L. L., Manoguerra, A. S., Nelson, L. S., Christianson, G., Troutman, W. G., American Association of Poison Control Centers (November 2007). "Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management". *Clinical Toxicology (Philadelphia, Pa.)*. **45** (7): 737â€“752. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1080/15563650701665175](//doi.org/10.1080%2F15563650701665175). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1556-3650](//www.worldcat.org/issn/1556-3650).
27. [â†‘](#cite_ref-27) White, S. R., Yadao, C. M. (1 December 2000). ["Characterization of Methylphenidate Exposures Reported to a Regional Poison Control Center"](http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/archpedi.154.12.1199). *Archives of Pediatrics & Adolescent Medicine*. **154** (12): 1199. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1001/archpedi.154.12.1199](//doi.org/10.1001%2Farchpedi.154.12.1199). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1072-4710](//www.worldcat.org/issn/1072-4710).
28. [â†‘](#cite_ref-28) 2012 Annual Report of the American Association
of Poison Control Centers â€™ National Poison
Data System (NPDS): 28th Annual Report | <https://aapcc.s3.amazonaws.com/pdfs/annual_reports/2012_NPDS_Annual_Report.pdf>
29. [â†‘](#cite_ref-29) Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., Wigal, S. (September 1999). "Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children". *Clinical Pharmacology and Therapeutics*. **66** (3): 295â€“305. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S0009-9236(99)70038-X](//doi.org/10.1016%2FS0009-9236%2899%2970038-X). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0009-9236](//www.worldcat.org/issn/0009-9236).
30. â†‘ [30.0](#cite_ref-Volkow1999_30-0) [30.1](#cite_ref-Volkow1999_30-1) Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., Dewey, S. L., Hitzemann, R., Gifford, A. N., Pappas, N. R. (January 1999). "Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high"". *The Journal of Pharmacology and Experimental Therapeutics*. **288** (1): 14â€“20. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0022-3565](//www.worldcat.org/issn/0022-3565).
31. [â†‘](#cite_ref-31) Volkow, N. D., Swanson, J. M. (November 2003). ["Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD"](https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.160.11.1909). *American Journal of Psychiatry*. **160** (11): 1909â€“1918. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1176/appi.ajp.160.11.1909](//doi.org/10.1176%2Fappi.ajp.160.11.1909). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0002-953X](//www.worldcat.org/issn/0002-953X).
32. â†‘ [32.0](#cite_ref-Morton2000_32-0) [32.1](#cite_ref-Morton2000_32-1) Morton, W. A., Stockton, G. G. (October 2000). ["Methylphenidate Abuse and Psychiatric Side Effects"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC181133/). *Primary Care Companion to The Journal of Clinical Psychiatry*. **2** (5): 159â€“164. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1523-5998](//www.worldcat.org/issn/1523-5998).
33. [â†‘](#cite_ref-33) Klein-Schwartz, W. (April 2002). ["Abuse and toxicity of methylphenidate:"](http://journals.lww.com/00008480-200204000-00013). *Current Opinion in Pediatrics*. **14** (2): 219â€“223. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1097/00008480-200204000-00013](//doi.org/10.1097%2F00008480-200204000-00013). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1040-8703](//www.worldcat.org/issn/1040-8703).
34. [â†‘](#cite_ref-34) Spensley, J., Rockwell, D. A. (20 April 1972). ["Psychosis during Methylphenidate Abuse"](https://doi.org/10.1056/NEJM197204202861607). *New England Journal of Medicine*. **286** (16): 880â€“881. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1056/NEJM197204202861607](//doi.org/10.1056%2FNEJM197204202861607). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0028-4793](//www.worldcat.org/issn/0028-4793).
35. [â†‘](#cite_ref-35) Ritalin & Ritalin-SR Prescribing Information | <http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf>
36. [â†‘](#cite_ref-36) Patrick, K., Straughn, A., Minhinnett, R., Yeatts, S., Herrin, A., DeVane, C., Malcolm, R., Janis, G., Markowitz, J. (March 2007). ["Influence of Ethanol and Gender on Methylphenidate Pharmacokinetics and Pharmacodynamics"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188424/). *Clinical pharmacology and therapeutics*. **81** (3): 346â€“353. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1038/sj.clpt.6100082](//doi.org/10.1038%2Fsj.clpt.6100082). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0009-9236](//www.worldcat.org/issn/0009-9236).
37. [â†‘](#cite_ref-37) Markowitz, J. S., DeVane, C. L., Boulton, D. W., Nahas, Z., Risch, S. C., Diamond, F., Patrick, K. S. (June 2000). "Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol". *Drug Metabolism and Disposition: The Biological Fate of Chemicals*. **28** (6): 620â€“624. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0090-9556](//www.worldcat.org/issn/0090-9556).
38. [â†‘](#cite_ref-38) D'Souza S, Mayock S, Salt A (December 2017). "A review of in vivo and in vitro aspects of alcohol-induced dose dumping". *AAPS Open* (in English). **3** (1). [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1186/s41120-017-0014-9](//doi.org/10.1186%2Fs41120-017-0014-9) ![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [2364-9534](//www.worldcat.org/issn/2364-9534).
39. [â†‘](#cite_ref-39) Jain, R; Stark, JG (September 2016). "Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications". *Postgraduate medicine*. **128** (7): 672â€“81. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1080/00325481.2016.1218259](//doi.org/10.1080%2F00325481.2016.1218259). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [27467139](//www.ncbi.nlm.nih.gov/pubmed/27467139).
40. [â†‘](#cite_ref-40) Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". *Journal of Medical Toxicology*. **5** (2): 63â€“67. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/BF03161089](//doi.org/10.1007%2FBF03161089). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1937-6995](//www.worldcat.org/issn/1937-6995). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1556-9039](//www.worldcat.org/issn/1556-9039). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [163567183](//www.worldcat.org/oclc/163567183).
41. [â†‘](#cite_ref-41) Gillman, P. K. (2005). ["Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity"](https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext). *British Journal of Anaesthesia*. **95** (4): 434â€“441. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/bja/aei210](//doi.org/10.1093%2Fbja%2Faei210) ![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1471-6771](//www.worldcat.org/issn/1471-6771). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0007-0912](//www.worldcat.org/issn/0007-0912). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [01537271](//www.worldcat.org/oclc/01537271). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [16051647](//www.ncbi.nlm.nih.gov/pubmed/16051647).
42. [â†‘](#cite_ref-42) "Green List: Annex to the annual statistical report on psychotropic substances (form P)" (PDF). Archived from the original (PDF) on 31 August 2012. (1.63 MB) 23rd edition. August 2003. International Narcotics Board, Vienna International Centre. Retrieved 2 March 2006.
43. [â†‘](#cite_ref-43) ["POISONS STANDARD DECEMBER 2019"](https://www.legislation.gov.au/Details/F2019L01471). Office of Parliamentary Counsel. Retrieved December 24, 2019.
44. [â†‘](#cite_ref-44) ["SCHEDULE III"](https://web.archive.org/web/20110416090043/http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-32.html#h-28). Department of Justice. Archived from [the original](http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-32.html#h-28) on April 16, 2011. Retrieved December 24, 2019.
45. [â†‘](#cite_ref-45) [*ArrÃªtÃ© du 22 fÃ©vrier 1990 fixant la liste des substances classÃ©es comme stupÃ©fiants*](https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/)
46. [â†‘](#cite_ref-46) [*Anlage III BtMG - Einzelnorm*](http://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html)
47. [â†‘](#cite_ref-47) [*Narkotikastrafflag (1968:64) (NSL), Lagen.nu*](https://lagen.nu/1968:64)
48. [â†‘](#cite_ref-48) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
49. [â†‘](#cite_ref-49) <https://www.titck.gov.tr/dinamikmodul/43>
50. [â†‘](#cite_ref-50) [*Misuse of Drugs Act 1971*](https://www.legislation.gov.uk/ukpga/1971/38/schedule/2)
51. [â†‘](#cite_ref-BreindahlHindersson2012_51-0) Breindahl, Torben; Hindersson, Peter (2012). "Methylphenidate is Distinguished from Amphetamine in Drug-of-Abuse Testing". *Journal of Analytical Toxicology*. **36** (7): 538â€“539. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/jat/bks056](//doi.org/10.1093%2Fjat%2Fbks056). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0146-4760](//www.worldcat.org/issn/0146-4760).